Program
mosapride
Also written as “Mosapride Citrate Injection(high)”, “Mosapride Citrate Injection(low)” and “Reference mosapride citrate (GASMOTIN)”.
Its studies are mostly in Gastritis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 10 open or running | phase 1since Dec 19, 2013 | Dec 19, 2013 | none ahead |
| IlDong Pharmaceutical | 10 open or running | phase 1since Mar 12, 2014 | Mar 12, 2014 | none ahead |
| Lunan Pharmaceutical Group | 11 open or running | phase 2since Jan 8, 2025 | Jan 8, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 19, 2013First study: phase 1 study in GastritisNew to GlaxoSmithKlineGlaxoSmithKline · NCT02201316 · 18 enrolled · India
- Mar 12, 2014IlDong Pharmaceutical's first study: phase 1 study in HealthyNew to IlDong PharmaceuticalIlDong Pharmaceutical · NCT02106130 · 40 enrolled · Korea, Republic of
- Jan 8, 2025Lunan Pharmaceutical Group's first study: phase 2 study in Postoperative Gastrointestinal DysfunctionNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06782594 · 150 planned · China
TargetBeta
“Serotonin 3 (5-HT3) receptor antagonist; Serotonin 4 (5-HT4) receptor agonist”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06782594Postoperative Gastrointestinal Dysfunction · China | 2 | Recruiting | Lunan Pharmaceutical Group | Jun 2025 | 150 |
| NCT02106130Healthy · Korea, Republic of | 1 | Completed | IlDong Pharmaceutical | Jun 2013 | 40 |
| NCT02201316Gastritis · India | 1 | Completed | GlaxoSmithKline | Mar 18, 2014 | 18 |
How it is read
Names in the registry
- “Mosapride Citrate Injection(high)”, 1 entry
- “Mosapride Citrate Injection(low)”, 1 entry
- “Reference mosapride citrate (GASMOTIN)”, 1 entry
- “Mosapride citrate”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.